Why is Medtronic (MDT) stock up today?
Medtronic stock is going up today, lifted by a Baird price-target raise and a sector read-through suggesting the medical-device group will hold up better than Johnson & Johnson's mixed quarterly report implied.
What happened
Medtronic shares rose 1.48% to $80.47 on July 16, recovering from the prior day's sector-wide pullback as medical-device stocks broadly stabilized. The move has two near-term catalysts: Baird raised its price target on Medtronic to $91 from $85 on July 14 — while keeping a Neutral rating — and a subsequent Investor's Business Daily analysis argued that Johnson & Johnson's disappointing quarterly report actually bodes well for device makers such as Intuitive Surgical, Abbott, and Medtronic, separating pharma-driven weakness in JNJ from the device segment's underlying demand.
The sector had stumbled the day before, when a separate report noted that a group of medical giants including Intuitive Surgical, Abbott, Stryker, and Medtronic sold off together. That pullback appears to have been short-lived for Medtronic, as the JNJ read-through analysis encouraged buyers to step back in. An additional spotlight came from ChartMill, which flagged Medtronic as a top dividend stock, citing its 3.50% dividend yield and a 10-year dividend growth history — a profile that tends to attract income-oriented buyers during uncertain markets.
The broader market backdrop is mildly supportive. The S&P 500 gained 0.38% today, though the Nasdaq (QQQ) dipped 0.27%, suggesting money is rotating into more defensive, dividend-paying names like Medtronic rather than high-growth tech. This week's macro data — CPI and PPI readings that came in near forecasts — have reduced some near-term inflation anxiety, easing pressure on rate-sensitive, large-cap healthcare stocks.
Fundamentally, Medtronic carries a $103 billion market cap, a trailing price-to-earnings ratio of 21.3, and a notably lower forward P/E of 12.6, suggesting the market expects earnings to expand meaningfully. The most recent quarter showed earnings per share of $1.55 against an estimate of $1.54, on revenue of $9.81 billion, with reported earnings growth of 18.3% and revenue growth of 9.9%. The stock currently sits between its intraday low of $79.46 and high of $81.88.
The catalysts, cited
Baird raises Medtronic price target to $91 from $85, maintains Neutral rating
MT Newswires
Analysis argues JNJ's mixed report bodes well for Intuitive Surgical, Abbott, Medtronic, and other device makers
Investor's Business Daily
Medtronic flagged as a top dividend stock with 3.50% yield and 10-year growth history
ChartMill
Medical device group including Medtronic suffered a sector-wide pullback the prior session
Investor's Business Daily
Why is JNJ moving?
Why is ISRG moving?
Why is ABT moving?
Why is SYK moving?People also ask
Why is Medtronic stock going up today?
Medtronic is rising today after Baird lifted its price target to $91 from $85, and after an analysis suggested that Johnson & Johnson's mixed quarterly report signals strength — not weakness — for device makers like Medtronic. The stock is also recovering from a sector-wide pullback the prior session.
What did Baird say about Medtronic stock?
On July 14, Baird raised its price target on Medtronic to $91 from $85 while maintaining a Neutral rating, indicating a more constructive view on the stock's valuation without an outright buy recommendation.
Is Medtronic up because of earnings?
Not directly — no new earnings were reported today. Medtronic's most recent quarterly results showed EPS of $1.55 versus an estimate of $1.54 on revenue of $9.81 billion, with 18.3% earnings growth. Today's move is driven by the analyst price-target raise and a sector read-through from JNJ's report.
Is it just Medtronic or is the whole medical device sector going up?
The broader medical device sector is stabilizing today after a group sell-off that included Intuitive Surgical, Abbott, Stryker, and Medtronic the prior session. The S&P 500 is up 0.38% overall, providing a supportive backdrop, though the Nasdaq is slightly negative, pointing toward rotation into defensive healthcare names.